Search

Displaying results 7301 - 7310 of 10000 in total
  1. Drug

    BMS-754807

    go.drugbank.com/drugs/DB15399
    Investigational

    BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).

  2. Drug

    Technetium Tc-99m epratuzumab

    go.drugbank.com/drugs/DB15452
    Experimental

    Technetium Tc-99m epratuzumab is under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma).

  3. Drug

    Diflomotecan

    go.drugbank.com/drugs/DB16138
    Investigational

    Diflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).

  4. Drug

    Eltanexor

    go.drugbank.com/drugs/DB16153
    Investigational

    Eltanexor is under investigation in clinical trial NCT02649790 (Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/refractory Cancer Indications).

  5. Drug

    Tiropramide

    go.drugbank.com/drugs/DB13091
    Investigational

    Tiropramide is under investigation in clinical trial NCT01629212 (Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome).

  6. Drug

    WGc-0201

    go.drugbank.com/drugs/DB22819
    Investigational

    WGc-0201 is under investigation in clinical trial NCT07077369 (WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy).

  7. Drug

    RSV-604

    go.drugbank.com/drugs/DB15197
    Investigational

    RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).

  8. Drug

    Dicloxacillin

    go.drugbank.com/drugs/DB00485
    ApprovedInvestigationalVet approved

    One of the penicillins which is resistant to penicillinase.

  9. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).

  10. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16713
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.